Bisphosphonates in cancer therapy.
Bisphosphonates are the standard of care in the treatment of malignant bone diseases, because of their ability to inhibit osteoclast-mediated bone destruction. We review here preclinical evidence that bisphosphonates also exert direct antitumour effects and antiangiogenic properties. Furthermore, we describe new insights on how bisphosphonates may act synergistically in combination with antineoplastic drugs or gammadelta T cells to exhibit antitumour activity. These findings reveal new exciting possibilities to fully exploit the antitumour potential of bisphosphonates in the clinical practice.
Stresing
Verena
V
INSERM, Research Unit U.664, Faculté de Médecine Laennec, Rue Guillaume Paradin, F-69372 Lyon cedex 08, France. verena.stresing@lyon.inserm.fr
Daubiné
Florence
F
Benzaid
Ismahène
I
Mönkkönen
Hannu
H
Clézardin
Philippe
P
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D017209:Apoptosis; D001842:Bone and Bones / Q000378:metabolism; D002448:Cell Adhesion; D049109:Cell Proliferation; D004164:Diphosphonates / Q000737:chemistry / Q000627:therapeutic use*; D004195:Disease Models, Animal; D006801:Humans; D008954:Models, Biological; D008956:Models, Chemical; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000188:drug therapy*
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D004164:Diphosphonates